Table 2.
Test results of the patient and her parents
| Father | Mother | Patient (46, XX) | |||
|---|---|---|---|---|---|
| Baseline | 3 months after treatment | 6 months after treatment | |||
| age (y) | 55 | 54 | 27 | ||
| FT (pmol/L) | 116.00 (55.05–183.50) | 6.42 (0.77–33.03) | 6.10 (0.77–33.03) | – | 5.38 |
| SHBG (nmol/L) | 9.00 (13.00–71.00) | 48.50 (18.00–114.00) | 80 (18.00–114.00) | – | 78 |
| T (nmol/L) | 27.70 (9.08–55.23) | <0.69 (0.69–2.15) | <0.69 (0.69–2.77) | – | <0.69 |
| AND (nmol/L) | 4.76 (1.05–11.52) | 1.53 (2.09–10.82) | <1.05 (2.09–10.82) | – | <1.05 |
| DHEA (umol/L) | 1.70 (2.17–15.20) | 1.95 (0.95–11.67) | 0.76 (0.95–11.67) | – | 0.82 |
| E2 (pmol/L) | 117.0 (73.4–206.0) | 106.0 (73.4–110.0) | 244.0 (73.4–587.0) | 225 | 231 |
| P (nmol/L) | 1.17 (0.86–2.90) | <0.64 (0.64–3.20) | 8.68 (0.64–3.60) | 4.61 | 3.83 |
| 17OHP (ng/mL) | |||||
| Baseline | 0.80 (0.50–2.10) | 1.20 (0.13–0.51) | 9.60 (0.10–0.80) | 3.8 | 3.1 |
| 60 min after 25U ACTH iv | – | – | >20 | – | – |
| LH (mIU/mL) | 7.76 (0.80–7.60) | 50.60 (11.3–398.00) | 4.78 (1.10–11.60) | 2.72 | 2.73 |
| FSH (mIU/mL) | 12.30 (0.70–11.10) | 92.90 (21.70–153.00) | 7.14 (2.80–11.30) | 6.40 | 6.18 |
| PRL (mIU/mL) | 119.0 (40.0–530.0) | 111.0 (40.0–530.0) | 443.0 (40.0–530.0) | – | 383.2 |
| ACTH (pg/ml) | 48.71 (7.20–63.30) | 10.77 (7.20–63.30) | 48.75 (7.20–63.30) | 33.48 | 14.52 |
| COR (nmol/L) | |||||
| Baseline | 497.8 (171.0–536.0) | 244.1 (171.0–536.0) | 198.5 (171.0–536.0) | 466.5 | 303.3 |
| 60 min after 25U ACTH iv | – | – | 642.3 | – | – |
T testosterone, FT free testosterone, AND androstendione, SHBG sex-hormone binding globulin, DHEA dehydroepiandrosterone, E2 estradiol, ACTH adrenocorticotropic hormone, COR cortisol, LH luteinizing hormone, FSH follicle-stimulating hormone, PRL prolactin, 17OHP 17-hydroxyprogesterone, P progesterone